Brighi N, Panzuto F, Modica R, et al. - Researchers undertook this retrospective study to assess biliary stone disease incidence, complications, and risk factors among somatostatin analog (SSA)-treated patients with neuroendocrine tumors (NETs), given a common side effect of SSAs is biliary stone disease. Of 478 patients included, 118 (24.7%) were given prophylactic ursodeoxycholic acid (UDCA). The development of biliary stone disease was reported in 129 patients (27.0%) throughout the study. Of these, 36 (27.9%) suffered biliary complications. Independent risk factors for biliary stone disease, as revealed in multivariate analysis, were primary gastrointestinal (GI)-NET and related surgery. Findings revealed a high incidence of biliary stone disease especially in GI-NET or GI surgery. No protective effect of UDCA prophylaxis appeared. Considering prophylactic cholecystectomy was recommended for all patients with primary GI-NET or undergoing abdominal surgery; no inference could be reached about the indication of prophylactic cholecystectomy in patients suffering from primary pancreatic or thoracic NET for whom abdominal surgery is not planned.